Cocrystal Pharma, Inc. (COCP): R&D Expense
$5.05M
Year ended 2025-12-31
$6.09M
Trailing 12 months to 2026-06-30
-25.8%
3-year compound annual growth
-3.5%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.05M | -59.7% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $12.54M | -17.4% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $15.17M | +22.4% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $12.39M | +40.9% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $8.79M | +45.7% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $6.03M | n/c | 2022-03-23, From 2020-01-01 |
| 2019-12-31 | $4.00M | -14.2% | 2021-03-17, From 2019-01-01 |
| 2018-12-31 | $4.67M | -19.8% | 2020-03-27, From 2018-01-01 |
| 2017-12-31 | $5.82M | -94.3% | 2019-04-01, From 2017-01-01 |
| 2016-12-31 | $101.68M | +115.1% | 2018-03-21, From 2016-01-01 |
| 2015-12-31 | $47.26M | n/m | 2018-03-21, From 2015-01-01 |
| 2014-12-31 | $4.07M | +5.4% | 2017-03-31, From 2014-01-01 |
| 2013-12-31 | $3.86M | +689.2% | 2015-03-31, From 2013-01-01 |
| 2012-12-31 | $489.3K | n/c | 2014-03-31, From 2012-01-01 |
| 2011-12-31 | $423.2K | n/c | 2013-04-01, From 2011-01-01 |
| 2010-12-31 | $240.9K | n/a | 2012-04-16, From 2010-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | 2025-12-31 | $5.05M | -59.7% |
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | $453.7K | -95.5% |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $7.41M | +64.5% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $6.69M | +16.3% |
| Kala Bio, Inc. (KALA) | 2025-12-31 | $18.78M | -15.0% |
| Korsana Biosciences, Inc. (KRSA) | 2025-12-31 | $959.0K | +235.3% |
| Medicus Pharma Ltd. (MDCX) | 2025-12-31 | $7.72M | +118.9% |
| Oragenics Inc (OGEN) | 2025-12-31 | $2.39M | -41.8% |
| Indaptus Therapeutics, Inc. (INDP) | 2025-12-31 | $9.34M | +28.8% |
Compare COCP, MAIA, FBLG, CANF side by side · Screen every company in Pharmaceutical Preparations ↗